

October 24, 2007



# **GelStat Updates Shareholders on Marketing and Fulfillment Agreement With Icarus Medical Industries**

## **Receipt of \$200,000 Purchase Order Contingent on Ministry of Health Approval in Kuwait**

ST. PAUL, MN -- (MARKET WIRE) -- 10/24/07 -- GelStat Corporation (PINKSHEETS: GSAC), a consumer healthcare company primarily focused on the development and marketing of over-the-counter (OTC) products for the safe and effective treatment of pain and inflammation, is pleased to announce it received a \$200,000 purchase order from Icarus Medical Industries Co. for GelStat Migraine. The purchase order is contingent on approval from the Ministry of Health in Kuwait and is the first three expected orders to roll out the product throughout the Middle East.

Tom DeSantis, of US Marketing, the business development company hired by GelStat, said, "While this purchase order is contingent on approval of the Ministry of Health, it represents another significant milestone. Furthermore, we have completed and submitted all of the paperwork required by the Ministry of Health for approval and will do everything in our power to expedite the process."

Bill Colucci, GelStat's President, commented, "In addition to numerous unsolicited testimonials the Company has received, the research completed by Icarus prior to issuing its purchase order is another affirmation of the efficacy and potential success of this single product."

### **ABOUT GELSTAT CORPORATION**

GelStat Corporation is dedicated to providing safe and effective over-the-counter (OTC) treatments for pain and inflammation. GelStat's first product, GelStat Migraine, is sold nationwide through retail chain stores, independent retailers and pharmacies, and direct to consumer channels. GelStat Migraine is a sublingually (under the tongue) administered OTC medication for acute relief from the pain and associated symptoms of migraine. Over 90 percent of the 30 million Americans with migraine use OTC headache remedies, generally aspirin or other non-steroidal anti-inflammatory drugs. Americans spend \$2.6 billion each year on 600 million units of such products, although they are believed to be effective for only about 25 percent of those with moderate to severe migraine.

The Company also has a suite of additional, effective healthcare products that address large consumer markets. GelStat(TM) Arthritis is the second available product to utilize GelStat's patent-pending formulation and is provided as a daily use, sublingual dissolving

tablet. The Center for Disease Control estimates that, in its many forms, arthritis affects up to 70 million Americans. The Company has also developed "GelStat(TM) Sinus" and "GelStat(TM) Sleep," and believes that each of these products performs well and is effective for its intended use. The National Institute of Allergy and Infectious Disease estimates that 37 million Americans are affected by sinusitis every year, with at least 20 million more suffering from allergies. Approximately 70 million Americans are reported to be "problem sleepers."

For more information, visit [www.gelstat.com](http://www.gelstat.com)

#### Safe Harbor Statement Under the Private Securities Litigation Act of 1995

With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of GelStat could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rate and unanticipated events such as terrorist activities. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. For further risk factors, please review our SEC filings.

#### CONTACT:

Redwood Consultants, LLC  
415-884-0348  
[investorinfo@redwoodconsultants.com](mailto:investorinfo@redwoodconsultants.com)

or

Wall Street Resources, Inc.  
772-219-7525  
[www.wallstreetresources.net](http://www.wallstreetresources.net)